Literature DB >> 24342548

The antimicrobial protein short palate, lung, and nasal epithelium clone 1 (SPLUNC1) is differentially modulated in eosinophilic and noneosinophilic chronic rhinosinusitis with nasal polyps.

Yi Wei1, Wentong Xia1, Xingling Ye1, Yunping Fan2, Jianbo Shi1, Weiping Wen1, Pingchang Yang3, Huabin Li4.   

Abstract

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a highly heterogeneous disease with aberrant host defense responses. However, whether innate immunity is similarly impaired in patients with eosinophilic and those with noneosinophilic CRSwNP remains unclear.
OBJECTIVES: We sought to evaluate the expression and possible modulation of short palate, lung, and nasal epithelium clone 1 (SPLUNC1), an innate immune molecule, in the 2 CRSwNP subsets.
METHODS: Polyp tissue and uncinate processes were collected from 40 patients with CRSwNP, 27 patients with chronic rhinosinusitis without nasal polyps (CRSsNP), and 22 control subjects. Expression of SPLUNC1; Toll-like receptor (TLR) 2, TLR3, and TLR4; and the proinflammatory cytokines IL-1α, IL-4, IL-13, IL-17A, and IFN-γ was examined in nasal tissues. Additionally, SPLUNC1 expression in response to specific inflammatory stimulation was measured in cultured polyp epithelial cells and A549 cells.
RESULTS: Polyp tissues exhibited significantly decreased expression of SPLUNC1 and other innate immune molecules compared with uncinate process tissues from patients with CRSwNP (P < .05), patients with CRSsNP, and healthy control subjects. Moreover, the eosinophilic CRSwNP subset exhibited significantly decreased SPLUNC1 expression and numbers of submucosal glands, as well as significantly increased IL-4 and IL-13 mRNA levels, compared with the noneosinophilic subset (P < .05). Accordingly, SPLUNC1 expression in polyp epithelial cells was significantly inhibited by IL-4 and IL-13 stimulation in vitro but was significantly upregulated after stimulation with TLR agonists and glucocorticoids (P < .05).
CONCLUSION: Differential SPLUNC1 suppression between the eosinophilic and noneosinophilic CRSwNP subsets suggests that they possess distinct pathogenic mechanisms. This finding might benefit the design of appropriate therapeutic interventions targeted to each subset.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  BPI; Bactericidal/permeability-increasing protein; CRS; CRSsNP; CRSwNP; Chronic rhinosinusitis; Chronic rhinosinusitis with nasal polyps; Chronic rhinosinusitis without nasal polyps; GAPDH; Glyceraldehyde-3-phosphate dehydrogenase; H&E; Hematoxylin and eosin; High-power field; LPLUNC2; Long palate, lung, and nasal epithelium clone 2; MBP; Major basic protein; PAS; PEC; PLUNC; Palate, lung, and nasal epithelium clone; Periodic acid–Schiff; Polyp epithelial cell; Quantitative real-time PCR; SPLUNC1; Short palate, lung, and nasal epithelium clone 1; TLR; Toll-like receptor; chronic rhinosinusitis; cytokine; eosinophil; glucocorticoid; hpf; nasal polyps; qRT-PCR; submucosal gland

Mesh:

Substances:

Year:  2013        PMID: 24342548     DOI: 10.1016/j.jaci.2013.09.052

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  19 in total

Review 1.  Clinical and biological markers of difficult-to-treat severe chronic rhinosinusitis.

Authors:  Mauricio López-Chacón; Joaquim Mullol; Laura Pujols
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

2.  The effect of BPIFA1/SPLUNC1 genetic variation on its expression and function in asthmatic airway epithelium.

Authors:  Niccolette Schaefer; Xingnan Li; Max A Seibold; Nizar N Jarjour; Loren C Denlinger; Mario Castro; Andrea M Coverstone; W Gerald Teague; Jonathan Boomer; Eugene R Bleecker; Deborah A Meyers; Wendy C Moore; Gregory A Hawkins; John Fahy; Brenda R Phillips; David T Mauger; Azzeddine Dakhama; Shaan Gellatly; Nicole Pavelka; Reena Berman; Y Peter Di; Sally E Wenzel; Hong Wei Chu
Journal:  JCI Insight       Date:  2019-04-18

Review 3.  Eosinophilic chronic rhinosinusitis in East Asians.

Authors:  En-Tong Wang; Yan Zheng; Peng-Fei Liu; Li-Juan Guo
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

4.  Excessive periostin expression and Th2 response in patients with nasal polyps: association with asthma.

Authors:  Yi Wei; Renqiang Ma; Jia Zhang; Xingmei Wu; Guodong Yu; Xianting Hu; Jian Li; Zhuofu Liu; Wendong Ji; Huabin Li; Weiping Wen
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

5.  Predictive significance of arachidonate 15-lipoxygenase for eosinophilic chronic rhinosinusitis with nasal polyps.

Authors:  Zhuoping Liang; Bing Yan; Chang Liu; Ruyu Tan; Chengshuo Wang; Luo Zhang
Journal:  Allergy Asthma Clin Immunol       Date:  2020-09-16       Impact factor: 3.406

6.  Age-Related Increase of Collagen/Fibrin Deposition and High PAI-1 Production in Human Nasal Polyps.

Authors:  Ara Jo; Tae Gyu Choi; Jung Yeon Han; Mark H Tabor; Narasaiah Kolliputi; Richard F Lockey; Seong H Cho
Journal:  Front Pharmacol       Date:  2022-05-31       Impact factor: 5.988

Review 7.  Pathogenesis of nasal polyposis.

Authors:  K E Hulse; W W Stevens; B K Tan; R P Schleimer
Journal:  Clin Exp Allergy       Date:  2015-02       Impact factor: 5.018

Review 8.  Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis.

Authors:  Robert P Schleimer
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

9.  Crystal structure of the mouse innate immunity factor bacterial permeability-increasing family member A1.

Authors:  Michael S Little; Matthew R Redinbo
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2018-04-16       Impact factor: 1.056

10.  Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis.

Authors:  Gayatri B Patel; Elizabeth A Kudlaty; Amina Guo; Chen Yeh; Margaret S Kim; Caroline P E Price; David Conley; Leslie C Grammer; Ravi Kalhan; Robert C Kern; Kris G McGrath; Bruce K Tan; Sharon R Rosenberg; Robert P Schleimer; Stephanie S Smith; Whitney W Stevens; Kevin C Welch; Anju T Peters
Journal:  Allergy Asthma Proc       Date:  2021-09-01       Impact factor: 2.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.